BioMarin Takes One Step Closer To Profitability With Positive GALNS Data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The orphan drug company reported positive Phase III data on its candidate for patients with the rare disease MPS IV and expects to file GALNS for FDA approval in the first quarter.